Posted by Site Administrator on March 20, 2013
Mouse engineers presented the latest models overexpressing the amyotrophic lateral sclerosis gene fused in sarcoma (FUS) at “New Frontiers in Neurodegenerative Disease Research,” a Keystone Symposium held 4-7 February 2013 in Santa Fe, New Mexico. These animals have been four years in the making. This is a long time even for mice (see ARF related [...]
Categories: ALS News, Research News, Technology
| 
Tags: ALS, ALS arginine-514-guanine, ALS community, ALS FUS transgenic mice, ALS gene fused in sarcoma (FUS), ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, arginine-521-cysteine (R521C) mutation ALS, Dr. Udai Pandey, FUS transgene ALS, Gladstone Institutes in San Francisco., huntingtin, Lou Gehrig's disease, Louisiana State University Health Sciences Center in New Orleans, New Frontiers in Neurodegenerative Disease Research, PALS, progressive motor neuron disease, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Steven Finkbeiner, superoxide dismutase 1 (SOD1), TDP-43
| 
No comments
Posted by Site Administrator on February 12, 2013
Globs of protein clustered in the neurons that control muscles have long been the hallmark of amyotrophic lateral sclerosis (ALS), the fatal neurodegenerative disease also commonly known as Lou Gehrig’s disease. Now, a study of the most commonly found mutant gene in people with ALS reveals an unexpected origin of some of those sticky masses, a finding that may offer drug developers a new target for treatments.
Categories: Research News, Treatments
| Tags: ALS, ALS community, ALS research, ALS research funding, ALS treatments, ALS-FTD, amyotrophic lateral sclerosis, Barrow Neurological Institute in Phoenix, Bob Stehlin, Bryan Traynor, C9ORF72 gene, C9orf72 mutations, Dieter Edbauer, dipeptide repeat (DPR) proteins, GGGGCC-laden C9orf72, Lou Gehrig's disease, Ludwig Maximilians University Munich in Germany, National Institute on Aging in Bethesda Maryland, neurodegenerative process ALS, PALS, protein clusters ALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, TDP-43, University of Antwerp in Belgium
| No comments
Posted by Site Administrator on December 10, 2012
The ALS Therapy Development Institute (ALS TDI) and the Gladstone Institutes today announced the formation of a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.
Categories: Clinical Trials, Research News, Technology, Treatments
| Tags: 2012 Nobel Prize in Physiology or Medicine, Aestus Therapeutics, ALS, ALS community, ALS cure, ALS medical care, ALS research, ALS TDI, ALS Therapy Development Institute, ALS treatments, amyotrophic lateral sclerosis, Biogen Idec, Bob Stehlin, Gladstone Institutes, induced pluripotent stem cells, iPS cells, iPS-based ALS therapy, MDA, PALS, RASCALS Foundation, RGK Foundation, Robert A. Stehlin Campaign for ALS, Shinya Yamanaka, sporadic ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Steve Finkbeiner, Steve Perrin, TDP-43, TDP-43 protein, UCB, University of California, University of California at San Francisco
| No comments
Posted by Site Administrator on November 8, 2012
A key challenge to the development of new drugs based upon the genetic information derived from familial ALS, as well as genes associated with sporadic ALS, is to understand how mutations in the various genes produce a similar clinical and pathological phenotype.
Categories: Research News, Treatments
| Tags: ALS diagnosis, ALS diagnostics, ALS research, ALS treatments, amyotrophic lateral sclerosis, C9ORF72, dexpramipexole, familial ALS, FUS, Knapp, Lou Gehrig's disease, mitochondrial function, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1, TARDBP, TDP-43, Van Hoecke
| No comments
Posted by Site Administrator on October 10, 2012
Scientists hope that by creating models of disease in different animals—from flies to reprogrammed human stem cells—research will converge on an answer, or multiple answers. “I think you have to use all these models, with different mutations, in the hopes that there will be one that really does provide the breakthrough,” says Maniatis. For patients and families, that breakthrough can’t come soon enough.
Categories: Research News, Treatments
| Tags: Aaron Gitler, ALS cure, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, ataxin-2 gene, Bob Stehlin, Columbia University, Dana Alliance for Brain Initiatives, iPS cells, Kyoto University, Lou Gehrig's disease, motor neurons, Nancy Bonini, Nuedexta, PALS, polyglutamine, polyQ segment, RASCALS Foundation, RNA binding protein, Robert A. Stehlin Campaign for ALS, SCA2, Science Translational Medicine, Shinya Yamanaka, SOD1, spinocerebellar ataxia 2, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Stanford University, TDP-43, TDP-43 toxicity, The Dana Foundation, Tom Jessell, Tom Maniatis
| No comments
